486 related articles for article (PubMed ID: 19663669)
1. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
Scott SA; Jaremko M; Lubitz SA; Kornreich R; Halperin JL; Desnick RJ
Pharmacogenomics; 2009 Aug; 10(8):1243-55. PubMed ID: 19663669
[TBL] [Abstract][Full Text] [Related]
2. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.
Scott SA; Khasawneh R; Peter I; Kornreich R; Desnick RJ
Pharmacogenomics; 2010 Jun; 11(6):781-91. PubMed ID: 20504253
[TBL] [Abstract][Full Text] [Related]
3. New genetic variant that might improve warfarin dose prediction in African Americans.
Schelleman H; Brensinger CM; Chen J; Finkelman BS; Rieder MJ; Kimmel SE
Br J Clin Pharmacol; 2010 Sep; 70(3):393-9. PubMed ID: 20716240
[TBL] [Abstract][Full Text] [Related]
4. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.
Perera MA; Cavallari LH; Limdi NA; Gamazon ER; Konkashbaev A; Daneshjou R; Pluzhnikov A; Crawford DC; Wang J; Liu N; Tatonetti N; Bourgeois S; Takahashi H; Bradford Y; Burkley BM; Desnick RJ; Halperin JL; Khalifa SI; Langaee TY; Lubitz SA; Nutescu EA; Oetjens M; Shahin MH; Patel SR; Sagreiya H; Tector M; Weck KE; Rieder MJ; Scott SA; Wu AH; Burmester JK; Wadelius M; Deloukas P; Wagner MJ; Mushiroda T; Kubo M; Roden DM; Cox NJ; Altman RB; Klein TE; Nakamura Y; Johnson JA
Lancet; 2013 Aug; 382(9894):790-6. PubMed ID: 23755828
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.
Limdi NA; Wiener H; Goldstein JA; Acton RT; Beasley TM
Blood Cells Mol Dis; 2009; 43(1):119-28. PubMed ID: 19297219
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing warfarin dose requirements in African-Americans.
Momary KM; Shapiro NL; Viana MA; Nutescu EA; Helgason CM; Cavallari LH
Pharmacogenomics; 2007 Nov; 8(11):1535-44. PubMed ID: 18034618
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
[TBL] [Abstract][Full Text] [Related]
8. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
[TBL] [Abstract][Full Text] [Related]
9. Genetic and clinical predictors of warfarin dose requirements in African Americans.
Cavallari LH; Langaee TY; Momary KM; Shapiro NL; Nutescu EA; Coty WA; Viana MA; Patel SR; Johnson JA
Clin Pharmacol Ther; 2010 Apr; 87(4):459-64. PubMed ID: 20072124
[TBL] [Abstract][Full Text] [Related]
10. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.
Limdi NA; Arnett DK; Goldstein JA; Beasley TM; McGwin G; Adler BK; Acton RT
Pharmacogenomics; 2008 May; 9(5):511-26. PubMed ID: 18466099
[TBL] [Abstract][Full Text] [Related]
12. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
[TBL] [Abstract][Full Text] [Related]
13. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.
Perera MA; Gamazon E; Cavallari LH; Patel SR; Poindexter S; Kittles RA; Nicolae D; Cox NJ
Clin Pharmacol Ther; 2011 Mar; 89(3):408-15. PubMed ID: 21270790
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
Palacio L; Falla D; Tobon I; Mejia F; Lewis JE; Martinez AF; Arcos-Burgos M; Camargo M
Clin Appl Thromb Hemost; 2010 Feb; 16(1):83-90. PubMed ID: 19567378
[TBL] [Abstract][Full Text] [Related]
15. VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy.
Orsi FA; Annichino Bizzacchi JM; de Paula EV; Ozelo MC; Langley MR; Weck KE
Thromb Res; 2010 Sep; 126(3):e206-10. PubMed ID: 20615525
[TBL] [Abstract][Full Text] [Related]
16. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.
Scott SA; Edelmann L; Kornreich R; Desnick RJ
Am J Hum Genet; 2008 Feb; 82(2):495-500. PubMed ID: 18252229
[TBL] [Abstract][Full Text] [Related]
17. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.
Sconce EA; Khan TI; Wynne HA; Avery P; Monkhouse L; King BP; Wood P; Kesteven P; Daly AK; Kamali F
Blood; 2005 Oct; 106(7):2329-33. PubMed ID: 15947090
[TBL] [Abstract][Full Text] [Related]
18. Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.
Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary O
Int J Clin Pharm; 2012 Dec; 34(6):837-44. PubMed ID: 22851439
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.
Shalia KK; Doshi SM; Parikh S; Pawar PP; Divekar SS; Varma SP; Mehta R; Doctor T; Shah VK; Saranath D
J Assoc Physicians India; 2012 Dec; 60():34-8. PubMed ID: 23781667
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of coumarin dosing: prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population.
Djaffar-Jureidini I; Chamseddine N; Keleshian S; Naoufal R; Zahed L; Hakime N
Genet Test Mol Biomarkers; 2011 Nov; 15(11):827-30. PubMed ID: 21651319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]